Ruchit Patel is an antitrust partner in the firm’s London office and a member of the firm’s governing policy committee. He advises some of the largest companies in the world on matters before the European Commission, UK Competition and Markets Authority, UK sectoral regulators and UK High Court. He also has litigation experience before the UK Competition Appeal Tribunal.
Ruchit was included in Global Competition Review’s 2020 list of the top young antitrust lawyers in the world: the 40 under 40. Who’s Who Legal characterizes him as a “Future Leader” and comments that “Ruchit Patel is revered as a “skilled, flexible and sharp-minded competition law expert” who is “able to coordinate complex projects.” Ruchit is also recognized in Chambers UK in the area of competition law, and GCR notes he is a “Future Leader.” Clients have commented in Who’s Who Legal that Ruchit is “a very experienced competition lawyer” who “focuses on strategy and results” and “is uniquely dedicated to ensuring his clients’ success” and is “able to coordinate complex projects.” Legal 500 also noted that Ruchit brings “an in-depth knowledge of Indian competition law.”
Ruchit is a visiting lecturer at the Centre for Commercial Law Studies at Queen Mary University of London. He is a member of several committees, including the Competition Section of the English Law Society, the Law360 editorial board, and the editorial board of the IBA.
Experience
Ruchit has advised on some of the most significant and complex transactions of recent years. A selection of recent matters includes:
Life Sciences & Healthcare
- Pfizer on its ~$10 billion acquisition of Metsera — including successfully defending a bidding war on antitrust grounds before multiple agencies. Named GCR Antitrust Matter of the Year 2026.
- Eli Lilly on its agreement to acquire Ajax Therapeutics (up to $2.3 billion) and Ventyx Biosciences ($1.2 billion)
- Tanabe Pharma in the $2.5 billion sale of global rights to a leading ALS therapy to Shionogi
- ImmunoGen on the antitrust aspects of its ~$10.1 billion sale to AbbVie
- Becton Dickinson on its $4.2 billion acquisition of Edwards Lifesciences' Critical Care business and its $17.5 billion divestiture to Waters Corporation
- AbbVie on its acquisition of Mitokinin, a discovery-stage biotech developing treatments for Parkinson's disease
- Pfizer on multiple transactions including Biohaven (~$12 billion), Global Blood Therapeutics (~$5.4 billion), Trillium Therapeutics ($2.26 billion), and Medivation ($14 billion)
- Medtronic on several transactions including Covidien ($43 billion), Mazor Robotics ($1.64 billion), Affera (~$1 billion), and Intersect ($1.1 billion)
Private Equity
- EQT on its acquisition of global secondaries firm Coller Capital — understood to be the largest-ever secondaries fund manager acquisition
- Bain Capital on its $5.6 billion acquisition of PowerSchool Holdings, its $4.5 billion acquisition of Envestnet, its $3.4 billion acquisition of Mitsubishi Tanabe, and its landmark ~$18 billion acquisition of Toshiba Memory Corporation (by a Bain-led consortium including Apple, Dell, SK Hynix, and others)
- Bain Capital on the $8.5 billion acquisition of Hitachi Metals
- TPG on its $14 billion sale of McAfee Consumer to Advent and Permira, and its $4 billion sale of McAfee Enterprise to STG
- Leonard Green & Partners on its acquisition of a majority stake in Topgolf and Toptracer from Topgolf Callaway Brands
- Kohlberg and Montagu on the $1.5 billion carve-out acquisition of Teleflex Medical OEM
- THL Partners in the $1.65 billion sale of portfolio company AMI to Lattice Semiconductor
- Advent International on its $2.7 billion acquisition of Nielsen IQ and its $4.25 billion acquisition of Baxter BioPharma Solutions
- Warburg Pincus and General Atlantic on their $2 billion acquisition of Santander Asset Management
Technology & Industrials
- Nippon Steel on its ~$14 billion bid for US Steel
- Google on its $4.5 billion investment in Reliance Jio Platforms and on multiple multi-jurisdictional competition investigations
- Xerox on its $1.5 billion acquisition of Lexmark International
- Bloomberg on the antitrust aspects of its planned acquisition of Broadway Technology
- Hitachi Rail on its acquisition of Clever Devices
- National Amusements in the Skydance Media / Paramount Global transaction
Credentials
Publications
Presentations
Awards
Professional & Civic Activities
Disclaimer
Ropes & Gray International LLP is a limited liability partnership registered in Delaware, United States of America and is a recognised body regulated by the Solicitors Regulation Authority (with registered number 521000).